SLC25A21 and acute myeloid leukemia: To confirm whether SLC25A21 was a potential biomarker for AML, we first examined the mRNA transcript levels of SLC25A21 in the bone marrow of 236 newly diagnosed subjects with AML and 22 normal healthy individuals in our cohort.